Marker Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Marker Therapeutics is Juan Vera, benoemd in May2023, heeft een ambtstermijn van 1.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 585.25K, bestaande uit 68.2% salaris en 31.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.99% van de aandelen van het bedrijf, ter waarde $ 871.02K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 6.3 jaar.

Belangrijke informatie

Juan Vera

Algemeen directeur

US$585.3k

Totale compensatie

Percentage CEO-salaris	68.2%
Dienstverband CEO	1.5yrs
Eigendom CEO	3.0%
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	6.3yrs

Recente managementupdates

Recent updates

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22

Marker shares rise as it completes construction of its cGMP manufacturing facility

Jan 13

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Jan 05

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29

Marker Therapeutics EPS misses by $0.02

Nov 09

Analyse CEO-vergoeding

Hoe is Juan Vera's beloning veranderd ten opzichte van Marker Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$10m
Jun 30 2024	n/a	n/a	-US$10m
Mar 31 2024	n/a	n/a	-US$12m
Dec 31 2023	US$585k	US$399k	-US$14m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$582k	US$380k	-US$20m

Compensatie versus markt: De totale vergoeding ($USD 585.25K ) Juan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Juan is gestegen terwijl het bedrijf verliesgevend is.

CEO

Juan Vera (44 yo)

1.5yrs

Tenure

US$585,251

Compensatie

Dr. Juan F. Vera, MD, serves as Chief Executive Officer and President at Marker Therapeutics, Inc. since May 1, 2023 and serves as its Secretary and Treasurer. He has held various positions at the Center f...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Juan Vera	Co-Founder	1.5yrs	US$585.25k	2.99% $ 871.0k
Elizabeth Donnelly	Director of Administration	8.2yrs	geen gegevens	geen gegevens
Maria-Bernadette Madel	Director of Corporate Operations & External Communications	less than a year	geen gegevens	geen gegevens
Edmund Cheung	Vice President of Human Resources	1.8yrs	geen gegevens	geen gegevens
Monic Stuart	Chief Medical Officer	1.5yrs	geen gegevens	geen gegevens
Patricia Allison	Head of Clinical Operations	less than a year	geen gegevens	geen gegevens
Mary Newman	Head of Regulatory Affairs	less than a year	geen gegevens	geen gegevens
Robert Florkiewicz	Senior Director of Molecular Biology & Virology	no data	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

44yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MRKR wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Juan Vera	Co-Founder	6.1yrs	US$585.25k	2.99% $ 871.0k
Steven Elms	Independent Director	5.3yrs	US$76.14k	0.033% $ 9.7k
James Allison	Member of Scientific Advisory Board	6.5yrs	geen gegevens	geen gegevens
Malcolm Brenner	Member of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
Cliona Rooney	Member of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
Norman Eansor	Independent Chairman	6.1yrs	US$124.04k	0.041% $ 12.0k
Padmanee Sharma	Member of Scientific Advisory Board	6.5yrs	geen gegevens	geen gegevens
John Wilson	Independent Director	6.1yrs	US$63.44k	8.75% $ 2.5m
Helen Heslop	Member of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
Katharine Knobil	Independent Director	2.9yrs	US$79.67k	0.0017% $ 488.7

6.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MRKR wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

Marker Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Marker Therapeutics, Inc. Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics, Inc. Announces Resignation of Anthony Kim as Chief Financial Officer, Effective September 30, 2022

Marker Therapeutics, Inc., Annual General Meeting, May 24, 2022

Marker Therapeutics, Inc. Announces Frederick Wasserman Will Not Stand for Reelection as Director

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.47 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.48 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: US$1.59 loss per share (vs US$3.58 loss in FY 2022)

Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

New major risk - Share price stability

Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study

Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse

Second quarter 2023 earnings released: US$0.47 loss per share (vs US$1.11 loss in 2Q 2022)

Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen (Multitaa)-Specific T Cell Product Candidate, Mt-401

Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration

Marker Therapeutics, Inc. Reports Pre-Clinical Data of Its MT-601 multiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics, Inc. Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC

Marker Therapeutics Announces U.S. Food and Drug Administration Clearance of IND for MT-601, Its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Resignation of Anthony Kim as Chief Financial Officer, Effective September 30, 2022

Marker Therapeutics Wins $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 Artemis Trial of Mt-401 in Post-Transplant AML

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Nasdaq Grants an Additional 180-Calendar Day Compliance Period to Marker Therapeutics to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 41%

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Marker Therapeutics, Inc. Announces FDA Clearance of IND for Mt-601, the Six-Antigen Targeted T Cell Therapy for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Price target decreased to US$3.63

Marker Therapeutics, Inc., Annual General Meeting, May 24, 2022

Marker Therapeutics, Inc. Announces Frederick Wasserman Will Not Stand for Reelection as Director

Full year 2021 earnings: EPS misses analyst expectations

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Clinical Program Updates and Pipeline Expansion

Price target decreased to US$5.63

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from Russell 3000E Value Index

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Earnings beat expectations, revenue disappoints

Marker Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Trial of Mt-401 in Acute Myeloid Leukemia Following Stem Cell Transplant

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

New 90-day high: US$3.19

Marker shares rise as it completes construction of its cGMP manufacturing facility

New 90-day high: US$1.79

Marker Therapeutics, Inc. Announces U.S. Food and Drug Administration Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

New 90-day high: US$1.75

Earnings beat expectations

Marker Therapeutics EPS misses by $0.02

New 90-day low: US$1.43

New 90-day low: US$1.50

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from S&P Global BMI Index

New 90-day low - US$1.65

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur